The selection of ABI-6250 for IND-enabling studies indicates that Assembly Biosciences is making progress in its research and development efforts. If successful, these studies could lead to the development of a new treatment for chronic Hepatitis D Virus infection, which could potentially boost the company's revenues and profitability in the future. The same applies to their earlier selection of ABI-5366 for high-recurrence genital herpes. Both these developments are likely to have a positive impact on the company's stock price in the short term.